mild cognitive impairment

Persistent Depressive Symptoms After MCI Strongly Predict Progression to Alzheimer’s Disease

By MedXY 11/05/2025

In an ADNI longitudinal cohort, persistently elevated depressive symptoms over 36 months after MCI diagnosis were associated with a dose‑dependent, substantially higher hazard of conversion to Alzheimer’s disease over long-term follow-up.

Family Medicine & Nutrition Neurology Nursing & care Specialties

Evaluating Combined Mind-Body Exercise, Cognitive Training, and Nurse-Led Risk Factor Modification in Mild Cognitive Impairment: Insights from a Three-Arm Randomized Controlled Trial

By MedXY 10/20/2025

A large RCT in primary care showed no significant cognitive benefits of a combined intervention integrating mind-body physical exercise, cognitive training, and nurse-led risk factor modification over nurse-led risk factor modification alone or general health advice in mild cognitive impairment. Future refinements and research are needed.

Clinical Updates Neurology news

Clinically Meaningful Changes in Cognitive and Functional Measures Early in Alzheimer’s Disease: Insights from Population-Based Cohorts

By MedXY 09/28/2025

This review synthesizes evidence on clinically meaningful within-patient changes in cognitive and functional assessments among individuals transitioning to mild cognitive impairment (MCI), highlighting implications for clinical trials and early intervention in Alzheimer's disease and related dementias (ADRD).

Clinical Updates Neurology news Specialties

Sodium Benzoate as a Promising Treatment for Amnestic Mild Cognitive Impairment: Evidence from a Randomized Controlled Trial

By MedXY 08/27/2025

A 24-week randomized, double-blind trial shows sodium benzoate, a D-amino acid oxidase inhibitor, improves short-term memory in patients with amnestic mild cognitive impairment, suggesting a potential therapeutic role with a favorable safety profile.

Clinical Updates Diabetes & Endocrinology Neurology news Specialties

Impact of Dapagliflozin on Cognitive Function in Older Adults with Type 2 Diabetes and Mild Cognitive Impairment

By MedXY 08/11/2025

A 36-week study shows that dapagliflozin significantly improves cognitive function and metabolic parameters in middle-aged and older patients with type 2 diabetes and mild cognitive impairment.